HR
TXMD icon

Howe & Rusling’s TherapeuticsMD TXMD Stock Holding History

Howe & Rusling’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-20
Closed – – 992
2022
Q3 		$0 Buy
+20
New +$162 ﹤0.01% 1191
2022
Q2 		– Sell
-20
Closed – – 1163
2022
Q1 		$0 Buy
20
+6
+43% +$94 ﹤0.01% 1085
2021
Q4 		$0 Hold
14
– – ﹤0.01% 1070
2021
Q3 		$1K Hold
14
– – ﹤0.01% 947
2021
Q2 		$1K Hold
14
– – ﹤0.01% 910
2021
Q1 		$1K Buy
+14
New +$1.1K ﹤0.01% 915

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Howe & Rusling's TXMD Position: Q4 2022 in Review

Howe & Rusling sold out of TherapeuticsMD (TXMD) in Q4 2022, closing a stake of 20 shares.

Howe & Rusling first reported a position in TXMD in Q1 2021 and held it in 6 quarters. The position peaked at $1K in Q3 2021. 44 funds tracked by Wall St. Rank hold TXMD as of Q4 2022.

  • Howe & Rusling reported no remaining TherapeuticsMD position as of Q4 2022 after selling out during the quarter.
  • Howe & Rusling sold 20 TherapeuticsMD shares in Q4 2022.
  • Howe & Rusling first reported a position in TherapeuticsMD in Q1 2021 and held it in 6 quarters.
  • Howe & Rusling's TherapeuticsMD position peaked at $1K in Q3 2021.
  • 44 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2022.

Based on Howe & Rusling's 13F filing for Q4 2022, filed 15 Feb 2023.